Tyra Biosciences annual return on equity
2021
2022
2023
2024
2025
Tyra Biosciences Return on Equity (ROE) Growth & History (TYRA)
Tyra Biosciences's return on equity was −39.83% for fiscal 2025.
View full Tyra Biosciences company overviewTyra Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −39.83% | −8.23 pp |
| 2024 | 2024-12-31 | −31.60% | −1.67 pp |
| 2023 | 2023-12-31 | −29.92% | −10.15 pp |
| 2022 | 2022-12-31 | −19.77% | −1.52 pp |
| 2021 | 2021-12-31 | −18.25% | — |
Tyra Biosciences quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −12.29% | −3.31 pp |
| Q1 2026 | 2026-03-31 | −12.15% | −3.71 pp |
| Q4 2025 | 2025-12-31 | −12.54% | −5.29 pp |
| Q3 2025 | 2025-09-30 | −10.25% | −3.75 pp |
| Q2 2025 | 2025-06-30 | −8.98% | −4.10 pp |
| Q1 2025 | 2025-03-31 | −8.44% | −2.32 pp |
| Q4 2024 | 2024-12-31 | −7.25% | +3.46 pp |
| Q3 2024 | 2024-09-30 | −6.51% | +2.68 pp |
| Q2 2024 | 2024-06-30 | −4.88% | +0.56 pp |
| Q1 2024 | 2024-03-31 | −6.12% | −1.43 pp |
| Q4 2023 | 2023-12-31 | −10.71% | −5.80 pp |
| Q3 2023 | 2023-09-30 | −9.18% | −4.60 pp |
| Q2 2023 | 2023-06-30 | −5.45% | −0.15 pp |
| Q1 2023 | 2023-03-31 | −4.69% | +0.31 pp |
| Q4 2022 | 2022-12-31 | −4.91% | −1.66 pp |
| Q3 2022 | 2022-09-30 | −4.58% | −0.09 pp |
| Q2 2022 | 2022-06-30 | −5.30% | — |
| Q1 2022 | 2022-03-31 | −5.00% | — |
| Q4 2021 | 2021-12-31 | −3.25% | — |
| Q3 2021 | 2021-09-30 | −4.49% | — |
Tyra Biosciences return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Tyra Biosciences's return on equity decreased from −18.25% to −39.83%, a change of −21.57 percentage points. The latest reported quarter, Q2 2026, shows −12.29%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tyra Biosciences source filings ↗